Prospects For Clarification Of Gene Patents

Law360, New York (January 19, 2011, 4:04 PM EST) -- AMP et al. v. Myriad et al. has thrown into doubt the validity of patents claiming human genetic material. The ruling in the lower court, the U.S. District Court for the Southern District of New York, invalidated Myriad's claims for the BRACA 1 and BRACA 2 genes, critical for the diagnosis of susceptibility to breast and ovarian cancer.

The plaintiffs consisted of several learned medical societies, breast cancer patients and physicians. The defendants were originally the Myriad Corporation, the Trustees of the U. of Utah Foundation...
To view the full article, register now.